^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Onmel (itraconazole)

    Associations

    News

    Trials
    Company:
    Merz Pharma
    Drug class:
    CYP51A1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    29d
    KOMET-001: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=263, Active, not recruiting, Kura Oncology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed • First-in-human
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • MEIS1 (Meis Homeobox 1)
    |
    NPM1 mutation • KMT2A rearrangement
    |
    Komzifti (ziftomenib) • Onmel (itraconazole) • Tolsura (SUBA-itraconazole)
    3ms
    C2321001: A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma (clinicaltrials.gov)
    P1, N=453, Recruiting, Pfizer | Trial completion date: Mar 2029 --> Jul 2029
    Trial completion date
    |
    enzalutamide • Onmel (itraconazole) • Tolsura (SUBA-itraconazole) • mevrometostat (PF-06821497)
    12ms
    KOMET-001: First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1/2, N=263, Recruiting, Kura Oncology, Inc. | N=199 --> 263
    Enrollment change
    |
    NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A)
    |
    NPM1 mutation • KMT2A rearrangement
    |
    Komzifti (ziftomenib) • Onmel (itraconazole) • Tolsura (SUBA-itraconazole)